News

Bradley Burnam, founder and CEO of Turn Therapeutics, discussed interim phase 2 trial findings showing GX-03 efficacy across a broader range of EASI severity scores in atopic dermatitis.

A 30-day trial finds multi-step, barrier-friendly skin care routine cuts acne lesions, oil and redness while boosting hydration in acne-prone skin.

A recent JAAD study identified a dual Th17/Type 2 immune signature in psoriasis that may help explain why biologic responses vary among patients.

Teva Pharmaceuticals will advance TEV-'408 into phase 2b after encouraging phase 1b vitiligo data showed repigmentation, favorable safety, and quarterly dosing potential.

New case-control data link smoking to higher nail psoriasis severity, urging screening and cessation to ease nail symptoms and boost quality of life.

Turn Therapeutics finalized its stage 2 trial design after interim data showed clinically meaningful GX-03 efficacy in patients with baseline EASI scores as low as 1.1.

Philip Mease, MD, reviews the APEX trial data supporting guselkumab's expanded FDA label for inhibition of structural joint damage in psoriatic arthritis.

At a recent Dermatology Times Evolving Paradigms event, Nikhil Khushalani, MD, led dermatologists, Mohs surgeons, and oncologists in comparing systemic immunotherapy selection, referral practices, and adverse event management in advanced cutaneous squamous cell carcinoma.

Can-Fite completed interim enrollment for its pivotal phase 3 trial of first-in-class oral A3AR agonist piclidenoson, a potential new mechanism for plaque psoriasis.

LEADderm, led by Jennifer Soung, MD, helps dermatologists build leadership, AI readiness, and purpose-driven careers—leaving attendees energized, connected, and patient-focused.

Linda Stein Gold, MD, discusses zasocitinib's safety and efficacy as an oral treatment for plaque psoriasis.

Roman Bronfenbrener, MD, discusses how AI-generated patient diagnoses are reshaping dermatology visits and creating new challenges.

Kord Honda, MD, provides his first-line and adjunct treatment strategies for acne in recognition of Acne Awareness Month.

Explore top dermatology conferences and meetings in July 2026 and let us know which ones you'll be attending!

Linda Stein Gold, MD, reviews the recent LATITUDE Atlas head-to-head trial results showing zasocitinib's superiority over deucravacitinib for plaque psoriasis.

One-year phase 3 VELA data showed durable clinical responses, quality-of-life improvements, and no new safety signals for investigational sonelokimab in hidradenitis suppurativa.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Christopher Bunick, MD, PhD, discusses the FDA's expanded approval of roflumilast cream 0.3% for plaque psoriasis in children as young as 2 years of age.

AbbVie's upadacitinib received a positive CHMP opinion for severe alopecia areata as FDA review continues in the US.

Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.

A national survey examines the pressures facing independent dermatologists and strategies to strengthen practice performance.

The approval expands the existing indication for adults and children down to age 6, includes intertriginous areas, and removes restrictions on duration of use.

Philip Mease, MD, discusses the FDA's label expansion for guselkumab's inhibition of structural joint damage in psoriatic arthritis.

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Evommune's EVO756 failed to meet the primary end point in a phase 2b trial for chronic spontaneous urticaria, prompting the company to discontinue development for the indication while continuing studies in atopic dermatitis.

Despite often being highly treatable, nonmelanoma skin cancers account for millions of biopsies, procedures, and follow-up visits annually, creating a substantial healthcare burden.

Do nighttime collagen masks actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

The FDA has accepted Replimune's third resubmitted BLA for RP1 plus nivolumab in advanced melanoma, setting an August 2 PDUFA date.

Kord Honda, MD, reviews the hormonal drivers of acne, prevention-focused treatment, and common skin care misconceptions.

An Evolving Paradigms event led by Darrell S. Rigel, MD, MS, compared PD-1/PD-L1 immunotherapies for advanced cutaneous squamous cell carcinoma, with referral guidance and toxicity alerts.